CA2562859A1 — Novel enantiomerically pure beta-agonists, method for the production and the use thereof in the form of a drug

USPTO Abstract

The invention relates to enantiomerically pure compound of formula 1 (see formula 1) wherein R1 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy or halogen; R2 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy or halogen; R3 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy, halogen, OH, -O-C1-C4-alkylene-COOH or -O-C1-C4-alkylene-COO-C1-C4-alkyl; R4 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy or halogen; and X denotes an anion with a single negative charge, optionally in the form of a tautomer, mixture of tautomers, hydrate or solvate thereof. A method for producing said compounds and the use thereof in the form of a drug, in particular as a drug for treating respiratory tract diseases are also disclosed. The synthesis of the compounds is carried out by means of a chiral epoxide.